In its first major deal, BIND Biosciences has formed a collaboration with Amgen to develop and commercialise a kinase inhibitor nanomedicine for the treatment of a range of solid tumours. The partnership will leverage BIND’s Medicinal Nanoengineering® platform, which enables the design, engineering and manufacturing of targeted and programmable therapeutics called Accurins™. Therapeutic nanoparticles offer the potential to improve the efficacy and side-effect profile of new and existing drugs by maximising trafficking to disease sites and the deal is believed to be the first to apply tissue targeting to a molecularly targeted drug.